Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Axillary Dissection Using Carbon Marking for Patients With Node-positive Breast Cancer Following Neoadjuvant Therapy (TADCOM): a Prospective, Multicenter, Randomized Controlled Trial

NCT04744506 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT04744506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04744506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Axillary Dissection Using Carbon Marking for Patients With Node-positive Breast Cancer Following Neoadjuvant Therapy (TADCOM): a Prospective, Multicenter, Randomized Controlled Trial
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Overall status
Recruiting
Start date
November 30, 2024
Completion date
July 15, 2029
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lymph node metastases, surgery